

CIN: L24231MH1992PLC323914

Soc. Ltd., Akurli Road, Kandivali (East) Mumbai - 400101.

Ph: +91- 8655550242

compliance@genpharmasec.com

info@genpharmasec.com

www.genpharmasec.com

104 & 105, 1st Floor, Gundecha Industrial Premises Co-op

Date: March 27, 2024

BSE Limited,

P J Towers, Dalal Street, Fort, Mumbai – 400 001

REF. COMPANY CODE NO.: 531592

ISIN: INE861N01036

Subject: Intimation of Appointment of Company Secretary & Compliance Officer pursuant to Regulation
30 and other disclosures under SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015.

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Schedule III of said regulation, we would like to inform you that the Board of Directors of the Company at their meeting held today i.e. March 27, 2024 have inter-alia:

- Accepted Resignation of Mr. Ulhas Deosthale (DIN: 09215291), as Whole Time Director of the Company w.e.f. 12th March 2024;
- 2. Accepted Resignation of Ms. Heta Shah, as Company Secretary and Compliance Officer of the Company w.e.f. 20th March, 2024;
- 3. Mr. Hardik Makwana (Membership. No.: A72702) has been appointed by the Board as a Company Secretary & Compliance Officer of the Company w.e.f. 27th March 2024, in their Board Meeting held today based on the recommendation of Nomination & Remuneration Committee.

The details of resignation of Mr. Ulhas Deosthale (Director) and Ms. Heta Shah (Company Secretary) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/ CFO /CMD/4/2015 dated September 09, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023, is already being intimated to Exchange as Annexure 1 along with the resignation letters on their date of resignation itself.

Also, the details of appointment of Mr. Hardik Makwana (Company Secretary and Compliance Officer) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. CIR/ CFO /CMD/4/2015 dated September 09, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023, are given in the enclosed Annexure I.

We request you to take the above information on record and the same be treated as compliance under the applicable provision of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting was concluded at 05:10 PM.

Thanking You,

Yours Sincerely,
For Genpharmasec Limited,

SOHAN Digitally signed by SOHAN CHATURVEDI Date: 2024.03.27 17:13:04 + 05:30'



Annexure A

Information as required under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 read with Part A of Schedule III of the Listing Regulations and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015 and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 is as under:

Sr. No.	Particulars	Description
1.	Reason for change	Mr. Hardik Makwana has been appointed as the Whole Time Company Secretary & Compliance Officer of the Company (Key Managerial Personnel) of the Company w.e.f. 27th March, 2024.
2.	Date of cessation / resignation and term of appointment	27 th March, 2024
3.	Brief Profile	Mr. Hardik Makwana is an Associate Member of the Institute of Company Secretaries of India and has experience in dealing with matters of Companies Act, Listing Regulations and allied laws.
4.	Disclosure of relationships between Directors (in case of appointment as a Director).	Mr. Hardik Makwana is not related to any other Director of the Company.